Medicare obesity drug GLP-1 coverage starting July 1
Medicare is launching a temporary program to cover GLP-1 weight-loss drugs for millions of older Americans starting in July. While this expands access to medications like those from Novo Nordisk and Eli Lilly, experts warn of potential administrative hurdles and supply strain.
Why it matters
This represents a significant shift in federal healthcare policy that could impact millions of seniors and influence the long-term financial viability of obesity treatment coverage.
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs .
The article presents a balanced view of the benefits for patients alongside the logistical concerns of providers and the uncertainty of future funding.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in